Drugs News and Research

RSS

FDA approves Afinitor oral tablets (everolimus) for advanced form of kidney cancer

The U.S. Food and Drug Administration today approved Afinitor oral tablets (everolimus) for the treatment of patients with advanced kidney cancer whose disease has progressed after treatment with other cancer therapies.

30 Mar 2009

$78 billion spent for heart disease care in 2006

Opening blocked arteries, trying to keep heart attack victims alive, fixing defective heart valves, and treating other heart ailments cost $78 billion in 2006 - roughly 8 percent of the more than $1 trillion spent on all medical care for the community population, according to the latest News and Numbers from the Agency for Healthcare Research and Quality.

30 Mar 2009

The spread of drug resistant HIV-1

Drug-resistant forms of HIV can be spread between individuals who have not received anti-retroviral treatment, according to Professor Deenan Pillay from University College, London and the Health Protection Agency, speaking at the Society for General Microbiology meeting at Harrogate.

30 Mar 2009

War wounded at risk for superbugs

Soldiers who survive severe injuries on battlefields such as those in Iraq and Afghanistan can be at risk from developing infections of their wounds with multidrug resistant bacteria.

30 Mar 2009

Slow-growing tuberculosis bacteria point the way to new drug development

The discovery of a large number of slow-growing Mycobacterium tuberculosis bacteria, which cause tuberculosis (TB), in the lungs of TB patients could be an important step forward in the design of new anti-TB drugs.

30 Mar 2009

Discovery of new tumor suppressor gene

National Institutes of Health (NIH) researchers have identified a gene that suppresses tumor growth in melanoma, the deadliest form of skin cancer.

30 Mar 2009

Drug-coated stents lower risk of heart attack and death

Heart disease patients 65 and older who receive stents coated with medicine to prevent blockages are more likely to survive and less likely to suffer a heart attack than people fitted with stents not coated with medication, according to a new study supported by HHS' Agency for Healthcare Research and Quality and the American College of Cardiology's National Cardiovascular Data Registry.

30 Mar 2009

Angiogenesis inhibitor improves glioblastoma survival by reducing edema

The beneficial effects of anti-angiogenesis drugs in the treatment of the deadly brain tumors called glioblastomas appear to result primarily from reduction of edema - the swelling of brain tissue - and not from any direct anti-tumor effect, according to a study from Massachusetts General Hospital (MGH) researchers.

30 Mar 2009

Scientists, health officials increasing efforts to fight apread of drug-resistant malaria along Thai-Cambodian border

Scientists and health officials are increasing efforts to curb a drug-resistant malaria strain along the Thai-Cambodian border that is becoming increasingly resistant to artemisinin, an ingredient in artemisinin-based combination therapies, IRIN News reports.

30 Mar 2009

Senate measure would allow generic versions of biotechnology drugs after five years

Sens. Charles Schumer (D-N.Y.) and Susan Collins (R-Maine) on Thursday introduced legislation (S 726) that would allow FDA to approve generic versions of biotechnology drugs after a five-year period of brand-name patent exclusivity, the New York Times reports.

30 Mar 2009

HIV/AIDS advocates voice opposition to medication co-payments included in proposed New Jersey budget

People living with HIV/AIDS in New Jersey could be negatively affected by prescription drug co-payments included in Gov. Jon Corzine's (D) proposed $29.8 billion budget, advocates told state lawmakers on Tuesday, the Newark Star-Ledger reports.

30 Mar 2009

New high-throughput screening technique makes probing puzzling proteins possible

Understanding the tens of thousands of proteins that compose the human proteome has emerged as a key challenge of this century, and research efforts to date have already enabled major advances in drug discovery and understanding basic biology.

29 Mar 2009

Discovery of tuberculosis bacterium enzyme paves way for new TB drugs

A team of University of Maryland scientists has paved the way for the development of new drug therapies to combat active and asymptomatic (latent) tuberculosis infections by characterizing the unique structure and mechanism of an enzyme in M. tuberculosis, the bacterium that causes the disease.

29 Mar 2009

Dapagliflozin trial results indicate improvement in key glycemic measures in treatment-naive type 2 diabetes

Findings published in Diabetes Care from a 12-week, Phase IIb dose-ranging study showed that dapagliflozin, a novel, selective, sodium glucose co-transporter2 (SGLT2) inhibitor, produced clinically meaningful reductions across all key glycemic measures studied [glycosylated hemoglobin level (HbA1c), fasting plasma glucose (FPG), and postprandial plasma glucose (PPG)] in treatment-naive type 2 diabetes patients, compared to placebo.

29 Mar 2009

A comparative analysis of four beta blocker trials

ARCA biopharma, Inc. has announced that a comparative analysis of primary endpoint data from four beta blocker trials was presented at the American College of Cardiology 58th Annual Scientific Session being held March 29-31, 2009.

29 Mar 2009

Clinical effectiveness of coronary stents in the elderly

29 Mar 2009

Researchers reveal mechanism that regulates cancer-causing gene

Two University of Rhode Island scientists have revealed how a cancer causing protein is regulated by reactive oxygen species (ROS) -- a type of stress signal.

29 Mar 2009

Scientists discover structure of a protein that makes cancer cells resistant to chemotherapy

A research team at the Scripps Research Institute has obtained the first glimpse of a protein that keeps certain substances, including many drugs, out of cells.

29 Mar 2009

Protein from tick saliva shows potential for myasthenia gravis treatment

Looking for a better treatment for the autoimmune disease myasthenia gravis, researchers have found that a protein in tick saliva shows promise in limiting the severity of the disease in an animal model in a study published in the Annals of Neurology.

29 Mar 2009

Positive phase 3 uveitis trial results for voclosporin

Isotechnika Inc. has announced that their partner, Lux Biosciences, Inc., reported the results from the three Phase 3 LUMINATE trials investigating voclosporin oral capsule (LUVENIQ or LX211) for the treatment of uveitis.

29 Mar 2009